Fetal Growth Retardation Clinical Trial
Official title:
Growth Hormone and Insulin Resistance in Children With Intrauterine Growth Restriction
Insulin resistance is common among children with low birthweight. Moreover, growth hormone treatment for ensuing short stature also causes insulin resistance. Our objective is to examine these processes. Insulin resistance has recently been linked to the accumulation of stores of fat in muscle cells which can be measured by MRI. We hypothesize that children who are short due to low birthweight have increased muscle fat stores, but that growth hormone treatment will paradoxically reverse this association. To test this hypothesis, muscle fat stores will be measured in children who are short due to low birthweight before and after receiving growth hormone therapy. Other parameters linked to insulin resistance (glucose tolerance, blood markers, and body composition) will also be assessed. This study may lead to ways to increase growth hormone safety and dose limitations.
Growth hormone (GH) is an effective height-enhancing treatment for short stature. One
underlying disorder is intrauterine growth restriction (IUGR). Increased growth enhances
quality of life as well as improving body composition, metabolism, and lipid distribution.
However, both GH therapy and IUGR can cause insulin resistance. Scientists have recently
linked insulin resistance to the accumulation of fat inside muscle cells (intramyocellular
lipids or IMCL). Although GH generally reduces overall body fat, its effect on IMCL has not
yet been examined. This association can be examined in children with IUGR initiating GH
treatment for short stature.
Hypothesis: Children with IUGR will have increased IMCL linked to insulin resistance, but GH
treatment may paradoxically reverse this association.
Objectives: To assess changes in IMCL during GH therapy and to increase our knowledge of GH
action.
Study design: Prepubertal children initiating a course of GH therapy indicated by persistent
short stature as a result of IUGR will be recruited to participate in a crossover study.
- IMCL (soleus and tibialis anterior) will be measured non-invasively by proton magnetic
resonance spectroscopy (1H-MRS)
- Body composition will be measured by DEXA and morphometry
- Whole body insulin sensitivity (IS) will be assessed by oral glucose tolerance
- Levels of plasma lipids and hormones will be measured
Endpoints: The primary endpoint will be to define the effect of GH on IMCL content in IUGR
children. Secondary endpoints will be (i) to compare the relationships between IMCL and IS
before and after GH therapy, and (ii) to identify the correlative changes in plasma hormones
and metabolites that may underlie the IMCL changes.
Significance: IMCL is anticipated to be a valuable probe for understanding GH effects on
glucose homeostasis. This study is intended to reveal strategies for enhancing GH efficacy
without compromising IS. New pharmacological approaches to manage GH-induced glucose
intolerance would be important in counteracting this limiting factor in GH dosing.
;
Observational Model: Case-Crossover, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT04502823 -
Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler
|
N/A | |
Not yet recruiting |
NCT03625518 -
Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes
|
Early Phase 1 | |
Completed |
NCT05176041 -
SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
|
||
Completed |
NCT02379728 -
Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth
|
N/A | |
Completed |
NCT01695070 -
Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Completed |
NCT04289350 -
Day to Day Variation in Fetal Heart Rate Variability
|
||
Recruiting |
NCT03662178 -
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
|
||
Recruiting |
NCT05023161 -
Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
|
||
Completed |
NCT02590536 -
A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
|
Phase 3 | |
Not yet recruiting |
NCT05029778 -
Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve
|
Phase 4 | |
Recruiting |
NCT05576207 -
BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR)
|
N/A | |
Active, not recruiting |
NCT05160649 -
Effect of Covid 19 Infection on Fetomaternal Outcome
|
||
Completed |
NCT02280031 -
Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.
|
Phase 2 | |
Recruiting |
NCT04389099 -
MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
|
||
Recruiting |
NCT06039319 -
Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
|
||
Recruiting |
NCT05651347 -
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction
|
Phase 3 | |
Recruiting |
NCT02336243 -
A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders
|
Phase 3 | |
Active, not recruiting |
NCT01594463 -
Routine Ultrasound Screening in the Third Trimester
|
N/A |